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Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal
proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique
challenges due to the complex molecular pathophysiology and incurable status of the disease at
this time. Given that MM is the second most common blood cancer with a characteristic and
unavoidable relapse/refractory state during the course of the disease, the development of new
therapeutic modalities is crucial. Belantamab mafodotin (belamaf, GSK2857916) is a first-in-class
therapeutic, indicated for patients who have previously attempted four other treatments, including
an anti-CD38 monoclonal antibody, a proteosome inhibitor, and an immunomodulatory agent.
In November 2017, the FDA designated belamaf as a breakthrough therapy for heavily pretreated
patients with relapsed/refractory multiple myeloma. In August 2020, the FDA granted accelerated
approval as a monotherapy for relapsed or treatment-refractory multiple myeloma. The drug was
also approved in the EU for this indication in late August 2020. Of note, belamaf is associated with the
following adverse events: decreased platelets, corneal disease, decreased or blurred vision, anemia,
infusion-related reactions, pyrexia, and fetal risk, among others. Further studies are necessary to
evaluate efficacy in comparison to other standard treatment modalities and as future drugs in this
class are developed.
Keywords: belantamab mafodotin; multiple myeloma; anti-B cell maturation antigen; antibody drug
conjugate; chronic pain
1. Introduction
Multiple Myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation
of plasma cells. This disease overproduces terminally differentiated B-cells and immunoglobulins,
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which crowd the bone marrow and result in end-organ damage and immune suppression. Consequently,
as levels of monoclonal paraproteins accumulate, patients suffer from anemia, infections due to immune
cell depletion, bone pain, increased calcium levels, and renal failure [1–3]. Multiple myeloma develops
stepwise from premalignant conditions, known as the monoclonal gammopathy of undetermined
significance (MGUS) and smoldering multiple myeloma (SMM). These conditions are defined by
detectable paraproteins in the blood and urine, do not cause end-organ damage, and, therefore,
do not require treatment [2]. However, MGUS and SMM have the potential to develop into MM once
paraproteins accumulate to levels high enough to cause damage to the bone marrow, kidney, and other
organs. With the presence of the clonal proliferation of plasma cells and evidence of end-organ damage,
the diagnosis of MM can be made.
The global incidence of multiple myeloma has markedly increased in recent years, accounting for
about 1.8% of all cancer cases [4,5]. This disease remains incurable for many patients and requires
novel drugs to combat the associated high mortality rates. Five-year survival rates for MM have
dramatically improved over the past decade with the advancement of treatment options such as
stem cell transplants, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibodies,
and immunomodulators [4,6]. However, the treatment of multiple myeloma presents a variety of
unique challenges due to the complex molecular pathophysiology, intra-clonal heterogeneity, and the
incurable status of the disease at this time. While the majority of patients respond to initial treatment,
most will relapse, and response to further treatment declines with subsequent relapses [1].
There is no current cure for multiple myeloma despite the development of targeted biologic agents
and immunotherapy in the past decade. Relapse and refractory disease remain considerable challenges
in the pharmacologic management of the disease. The first drug in its class, belantamab mafodotin-blmf
(brand name Blenrep) is a novel therapeutic agent recently approved by the FDA to treat relapsed
or treatment-refractory multiple myeloma. Belamaf is an immunoconjugate anti-B-cell maturation
antigen with high specificity for multiple myeloma cells [7]. For those with limited treatment options,
belamaf has the potential to dramatically change patient outcomes. The recent FDA approval of this
drug emphasizes the continued need for innovative medications with high safety profiles, particularly
those that improve quality of life and mitigate multiple myeloma disease progression.
2. Multiple Myeloma Epidemiology and Risk Factors
Multiple myeloma (MM) is a rare cancer that accounts for 1.8% of all new cancer cases in the
United States [2]. After lymphoma, MM is the second most common malignancy of the blood cell
lineage [8]. According to the National Cancer Institute, there will be an estimated 32,270 new cases and
12,830 deaths (2.1% of all cancers) in 2020 in the United States [9]. All cases of MM begin as the benign
condition called monoclonal gammopathy of undetermined significance (MGUS). MGUS can progress
to smoldering multiple myeloma (SMM), which has the potential to progress to MM. These conditions
are characterized by an increase in the amount of monoclonal immunoglobulin produced, but which
are asymptomatic and do not cause end-organ damage [2]. The risk of progression from MGUS and
SMM to the malignant form of MM is 1% and 10% per year, respectively [2]. In rare cases, MM has the
ability to progress further into Plasma Cell Leukemia (PCL), where plasma cells begin to proliferate
outside the bone marrow and accumulate in the bloodstream.
Older age, male sex, and African American race are the leading risk factors for the development
of MM. Data from the NIH show that the age-adjusted rates of new cases per 100,000 were higher in
males (8.8%) than females (5.7%), and highest in African Americans for both sexes [5]. The incidence
of MM is correlated to age, with a median age of 69 and the majority of patients diagnosed between
65–74 years. Multiple myeloma is rare in patients younger than 30 years [5]. Other factors associated
with increased risk include alcohol consumption, obesity, radiation exposure, and insecticides [2].
New effective therapy to treat multiple myeloma has increased 5-year survival rates from 25% in
the years 1975–1977 and 27% in 1987–1989 to 49% in the period 2005–2011 and 53.9% in the period
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2010–2016 [5,10]. The increase in survival rates is attributed to the approval of the autologous stem cell
transplant (ASCT), bortezomib, and thalidomide/lenalidomide [6].
3. Pathophysiology
Multiple myeloma begins as a clonal proliferation of post germinal center B-cells that produce
large amounts of monoclonal immunoglobulin and light chain protein. Primary genetic events trigger
disease progression, with most cases of MM being due to chromosomal translocations involving
the immunoglobulin-heavy chain (IGH) genes (which interfere with antibody class switching) and
aneuploidy [11]. Other genetic events involved in the pathogenesis of MM include chromosome
13 deletion, activating RAS and BRAF mutations, the dysregulation of MYC, mutations in the NF-kB
pathway, chromosome 17p loss with abnormalities in p53, a gain of chromosome 1q and a loss of
1p [12,13]. Of note, myeloma cells interact with the immune and bone marrow microenvironment,
leading to the uncoupling of bone remodeling. This process may be partially explained by the
activation of osteoclasts (RANKL/RANK interactions, increased MIP-1α, decreased osteoprotegerin)
and the suppression of osteoblast formation and differentiation (dysregulation of factors Dkk1, sFRP-2,
IL-3, Runx2 and TGF-β) [12]. Furthermore, multiple myeloma exhibits clonal heterogeneity and
clonal evolution, which impacts clinical presentation and drug sensitivity. The initial disease may be
characterized by a predominance of one clone that responds well to treatment. Yet another inciting
event may allow for a new clone with novel genomic abnormalities to emerge, resulting in disease
relapse. Some patients have been shown to have up to seven subclones [11,14].
Almost all cases of MM begin as the premalignant conditions Monoclonal Gammopathy of
Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). MGUS and SMM are
asymptomatic conditions that may progress to multiple myeloma if levels of monoclonal protein rise
and genetic alterations in plasma cells accumulate [3]. MGUS is clinically distinguished from MM as
having a serum monoclonal Ig of less than 3 g/dL, a bone marrow plasma cell content of less than 10%,
no evidence of end-organ damage, and a 1% annual risk of progression to MM. SMM is defined as
having a serum monoclonal Ig of greater than 3 g/dL, a bone marrow plasma cell content of greater
than 10%, and no detectable end-organ damage, and a 10% annual risk of progression to MM [12].
By acquiring any combination of the oncogenic events mentioned above, MGUS and SMM are able to
progress to MM, the malignant form of the disease.
4. Presentation
According to current IMWG guidelines, the diagnostic criteria for symptomatic multiple myeloma
includes one or more myeloma-defining events (MDE) in addition to either clonal bone marrow plasma
cells ≥10% or biopsy-confirmed bony or extramedullary plasmacytoma [15]. MDE include one or more
CRAB criteria (hypercalcemia, renal failure, anemia, lytic bone lesions) or one or more biomarkers of
malignancy. Laboratory analysis is key to diagnosis, as patients often present with vague symptoms,
such as nausea, vomiting, malaise, weakness, recurrent infections, or weight loss [3,16]. In a majority
of cases, laboratory tests show anemia, hypercalcemia, and/or proteinuria [3].
As plasma cells begin to proliferate, the bone marrow becomes crowded, and the ability of other
cell lines to produce mature cells can lead to anemia, thrombocytopenia, and neutropenia [1]. Anemia
is present in almost all patients during the disease course and can present with fatigue, dyspnea,
or angina [16,17]. A blood smear will show normochromic and normocytic anemia (mild macrocytosis
may be seen) with the possible rouleaux formation of red blood cells [17]. Hypercalcemia occurs less
frequently at the time of diagnosis. When symptomatic hypercalcemia arises, patients may present
with confusion, muscle weakness, constipation, anorexia, polyuria, and polydipsia. If levels rise to
dramatically high levels, severe complications, such as cardiac arrythmias or coma, may occur [17,18].
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As the level of the immunoglobulin light chain rises, the protein may deposit in the distal and
collecting renal tubules, causing renal impairment with a resulting rise in serum creatine levels
(≥2 mg/dL). Hypercalcemia and the use of NSAIDs can also contribute to renal impairment [17,19].
Patients may experience bone pain, commonly back pain. Lytic bone lesions, found in up to 80% of
cases, contribute to hypercalcemia due to increased osteoclast activity and bone resorption. As such,
patients are at increased risk for osteopenia and fractures [1,20]. Bone marrow crowding and low levels
of normal mature immunoglobulins in MM result in the suppression of immune cells, resulting in
infection as a common complication [1]. High levels of serum paraproteins can also increase blood
viscosity, increasing the risk of dyspnea, transient ischemic attack, retinal hemorrhage, blurry vision,
seizure, and deep venous thrombosis. The consequent reduction in platelet count can also lead to easy
bruising and bleeding [2,3].
5. Current Treatment of Multiple Myeloma
5.1. Overview
Treatment modalities have improved concomitantly with the progression in understanding of the
molecular pathogenesis of MM over the past twenty years [21]. The use of corticosteroids (prednisone
and dexamethasone) and alkylating agents (mainly melphalan and cyclophosphamide) as standard
therapies began in the mid-1960′s. Since the 1990′s, treatment protocols have included autologous stem
cell transplant (ASCT) for eligible patients [21]. Drug classes, including immunomodulatory drugs
(IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs), have become the cornerstone
of modern multiple myeloma therapy [21,22]. Combinations of these drug classes have become a
standard of care in newly diagnosed transplant-eligible or -ineligible patients, and are utilized in triplet
or quadruplet regimens relative to each patient’s unique clinical profile [23].
Despite these advances, a definitive cure for this disease remains elusive; relapse is inevitable,
and refractory disease requiring salvage therapy remains a considerable challenge [22,24–26]. This has
prompted the development of new biologic agents and immunotherapy in the past decade [21,26–28].
The optimal sequence and combination of novel immunotherapeutic strategies remains to be determined.
Current treatment options continue to evolve as we increase our understanding of multiple myeloma’s
complex molecular pathophysiology and resulting clinical implications (Table 1).
Table 1. Current Therapeutic Considerations for Multiple Myeloma.
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* currently under clinical development for use in multiple myeloma.
5.2. Anti-BCMA Compounds Under Development
In 2015, the FDA approved two mAbs, daratumumab and elotuzumab, which selectively target
MM cell glycoproteins CD38 and SLAMF7, respectively [21,69]. Several novel immunotherapeutic
approaches have emerged since this time. New therapies can target plasma cell-specific antigens to offer
an innovative approach to treatment optimization and options for relapsed/refractory disease [21,22].
B-cell maturation antigen (BCMA), a soluble transmembrane glycoprotein overexpressed in MM
cells, represents an important target for novel therapeutics. These modalities include antibody-drug
conjugates (ADCs) (belantamab mafodotin), bispecific T-cell engagers (BiTEs) (AMG 420), and CAR
T-Cell Therapies [21,70].
5.2.1. Anti-BCMA Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates act as a carrier to deliver cytotoxic agents into MM cells, leading to
targeted tumor cell lysis with reduced toxicity in non-targeted tissues. They are composed of a mAb,
a linker connecting the drug to the antibody, and the cytoxic drug. Similar to belamaf, a first-in-class
anti-BCMA ADC, there are several emerging anti-BCMA therapeutics currently under development
for use in multiple myeloma.
AMG 224 is a compound consisting of an anti-BCMA IgG1 antibody conjugated via a linker
(4-[N-maleimidomethyl] cyclohexane-1-carboxylate) to mertansine, an anti-tubulin inhibitor [71].
There is an ongoing phase I study of AMG 224 as monotherapy in heavily pre-treated patients with
relapsed or refractory multiple myeloma (NCT02561962). Similarly, MEDI2228 is an ADC using
tesirine, a pyrrolobenzodiazepine dimer, as a toxic payload to MM cells. Tesirine is a DNA cross-linking
agent with site-specific conjugation to BCMA-Ab1 via a valine-alanine dipeptide linker. MEDI2228
is internalized and trafficked to the lysosome where tesirine is released, resulting in DNA damage,
myeloma cell and myeloma progenitor cell death [72]. Current clinical testing is ongoing for its use in
the treatment of RRMM (NCT03489525).
HDP-101 is a compound in a new class of ADCs called antibody-targeted amanitin conjugates
(ATAC). Amanitin, a toxin contained in the Amanita phalloides death cap mushroom, selectively binds to
and inhibits the RNA polymerase II subunit A with high affinity. This results in a >1000-fold decrease
in transcription and protein synthesis, leading to cell apoptosis and death. Of note, HDP-101 utilizes
chemically synthesized amanitin as its toxic payload conjugated to the anti-BCMA mAb via a cathepsin
B protease linker [73,74]. A Phase Ia/Ib dose escalation and expansion study is expected to begin in
early 2021 to evaluate the effect of HDP-101 in patients with RRMM.
Other anti-BCMA ADCs currently in phase I trials for patients with RRMM include CC-99712
(NCT04036461) and SEA-BCMA, a naked anti-BCMA mAb without conjugate (NCT03582033).
5.2.2. Anti-BCMA Bi-Specific Antibodies (BiAbs)
Bi-specific antibodies are a novel potential therapy for patients with multiple myeloma. Bi-specific
T-cell engaging antibody (BiTEs) are a specific type of BiAb that transiently connect immune and
tumor cells through their interaction with both CD3 on the T-cell and tumor antigens on the surface of
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target tumor cells. The molecules are designed with two domains, one that binds CD3ε in the T-cell
receptor (TCR) complex and the other that recognizes BCMA on MM cells. The binding of CD3ε leads
to activation of cytotoxic T-cells which release perforin and granzymes to lyse the targeted tumor cells,
and interferon-γ which activates macrophages and immune cells [75,76].
Several anti-BCMA BiAbs are in ongoing clinical trials for patients with MM. These include AMG
420 (NCT03836053), AMG 701 (NCT03287908), CC-93269 (NCT03486067), Teclistamab (NCT04557098,
NCT03145181, NCT04586426, NCT04108195), TNB-383B (NCT03933735), PF-06863135 (NCT03269136,
NCT04649359), REGN5458 (NCT03761108) and REGN5459 (NCT04083534).
5.3. Novel Agents
Novel agents have further expanded the available therapeutic options for patients with
relapsed/refractory MM. Selinexor is a first-in-class Exportin-1 (XPO-1) inhibitor, granted accelerated
approval in July 2019 for patients with penta-refractory multiple myeloma. Other therapeutics in
this class include Filanesib (ARRY-520) and Venetoclax (ABT-199), a kinesin spindle protein inhibitor
(KSP) and selective BCL-2 inhibitor, respectively. Filanesib is the only KSP inhibitor that has shown
anti-tumor activity in clinical trials. It has demonstrated clinical efficacy in heavily pretreated multiple
myeloma patients and may be useful in combination with standard MM backbones, such as PIs and
IMiDs [61,62]. Both Filanesib and Venetoclax are under clinical investigation for extended indications,
alone and in combination regimens in patients with multiple myeloma.
Immunotherapy via adoptive cell transfer (ACT) is also a promising investigational MM treatment.
Current trials are exploring the use of autologous chimeric antigen receptor (CAR)-transduced T-cells,
in which host T-cells are engineered with viral vector recombinant DNA techniques. CAR T-cells are
then used to initiate a targeted immune response against antigens specific to MM cells [21,26,77].
5.4. Hematopoietic Stem Cell Transplant Eligibility
Given the recent expansion in therapeutic options, individualized treatment for MM is ever
evolving and guided by a variety of clinical parameters [24,27]. At this time, eligibility for ASCT and
risk-stratification are predominant determinants of the treatment course of newly diagnosed MM [15,23].
ASCT remains the standard for first-line treatment of newly diagnosed MM; therefore, phases of
management are generally defined, relative to transplant eligibility [24,78]. Various applications of
the aforementioned treatments are utilized, depending on a patient’s transplant status. Transplant
eligibility is primarily determined by age and existing comorbidities, since these factors predispose
patients to toxicity and influence a patient’s ability to endure treatment [24,79]. The majority of
randomized trials limit ASCT to patients ≤ 65 years of age without significant comorbidities, although
consensus regarding an age cutoff has not been established, and practice varies across institutions [79].
Contraindications for ASCT include significant cardiac or pulmonary disorders [24]. Transplant-eligible
patients typically undergo 3–4 cycles of the current standard induction therapy, which is a triplet
regimen consisting of bortezomib, lenalidomide, and dexamethasone (VRd). Transplant-ineligible
patients undergo 8–12 cycles of VRd induction therapy [23,79,80]. Patients undergoing ASCT are treated
with cytokines or chemotherapy, after which hematopoietic stem cells are mobilized into peripheral
blood and harvested by apheresis [81]. The stem cells can then be used for marrow reconstitution
following high-dose chemotherapy. The standard maintenance therapy for both transplant ineligible
patients and eligible patients following ASCT is lenalidomide [15].
6. Belantamab Mafodotin Drug Info
In August 2020, the FDA granted accelerated approval to belantamab mafodotin-blmf (belamaf)
as a monotherapy treatment for relapsed or treatment-refractory multiple myeloma. Belamaf is a
first-in-class biologic for patients who have previously attempted four other treatments, including an
anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent [82,83].
As the first approved anti-B cell maturation antigen (BCMA), the use of belamaf may have a large
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impact on improving progression-free survival in patients with multiple myeloma who have limited
remaining treatment options. BCMA is a cell surface receptor required for the survival of plasma
cells. The expression of BCMA can be detected on all CD138+ myeloma cells, but it is not expressed in
any other tissues. This receptor specificity allows belamaf to target only the malignant MM plasma
cells [7,84].
Belantamab mafodotin is associated with a high incidence (≥20%) of keratopathy [85]. To mitigate
such risks, an ophthalmic exam is recommended prior to and during belamaf therapy in order to assess
baseline vision and possible adverse eye effects. Dosage can be reduced or held if ocular toxicity such
as blurry vision, dry eyes, or corneal ulcers occurs. Belamaf should be discontinued if ocular toxicity is
severe [82]. Other less common adverse effects, such as thrombocytopenia, infusion-related reactions,
pyrexia, fatigue, nausea, constipation, diarrhea, arthralgia, back pain, decreased appetite, and upper
respiratory infection, have been reported [86]. The most common grade 3 or 4 laboratory abnormalities
(≥5%) include decreases in neutrophils, lymphocytes, platelets, and hemoglobin, along with increases
in gamma-glutamyl transferase and creatinine [82].
There is a paucity of data on the use of belantamab during pregnancy and breastfeeding. Because
belantamab is a large protein molecule, the amount excreted in breastmilk is postulated to be very low.
However, belantamab is conjugated with mafodotin, a small-molecule toxin, which may be excreted
into milk. As such, it is recommended that patients use effective contraception and avoid breastfeeding
while taking the medication and for 3 months after the last dose [87].
7. Belantamab Mafodotin Mechanism of Action
7.1. Antibody Drug Conjugate (ADC)
Belantamab mafodotin (Blenrep, GSK2857916 or J6M0-MMAF) is an antibody-drug conjugate
(ADC) that demonstrates a multifaceted mechanism of action based on three main components. ADCs
are a new class of cancer therapeutics that confer unique pharmacologic activity via mAbs covalently
conjugated to a cytotoxic agent via a specialized linker [28]. The mAb component of an ADC selectively
targets tumor cells and elicits a host immune response, while simultaneously delivering a cytotoxic
payload to the cell [25,86]. Belamaf consists of a humanized, afucosylated IgG1 mAb conjugated to
monomethyl auristatin-F (MMAF) via a protease-resistant maleimidocaproyl linker [25,70].
7.2. Target Antigen-B-Cell Maturations Antigen (BCMA)
The high specificity of belamaf for MM cells is a hallmark feature derived from the mAb component,
which targets B-Cell Maturation Antigen (BCMA). BCMA, a member of the tumor necrosis factor
receptor superfamily, is a notable tumor-associated antigen of particular interest due to almost exclusive
BCMA expression on mature B-cells and plasma cells. BCMA is integral to plasma cell maturation
and differentiation. BCMA is also overexpressed during the malignant transformation of plasma cells,
making it an ideal pharmacologic target in the treatment of MM [21,25,70]. B-cell activating factor
(BAFF) and APRIL (a proliferation-inducing ligand) are high-affinity ligands for BCMA that promote
proliferation and viability of MM cells in the bone marrow. BAFF is a BCMA agonist that induces
differentiation, proliferation, and antibody production [21,70]. The binding of belantamab to BCMA
receptors impedes the pro-survival cytokine-signaling effects of BAFF and APRIL on malignant plasma
cells [21,28].
7.3. Afucosylated Monoclonal IgG1 Antibody
Belamaf induces enhanced tumor cell lysis via natural killer cell-mediated antibody-dependent
cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) [28,70,86].
While naturally occurring IgG antibodies exhibit significant core-fucosylation on the N-glycan of the Fc
region, the IgG1 mAb in belantamab mafodotin is afucosylated. The removal of these fucosyl groups
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enhances IgG1 Fc binding affinity to FcγRIIIa (CD16) on natural killer cells, which is a well-known
strategy for augmenting effector cell ADCC of cancer cells [21,25,88].
7.4. Monomethyl Auristatin-F (MMAF) and Linker
After belamaf binds, the mAb drug complex is internalized, allowing MMAF to induce
apoptosis [82]. MMAF inhibits tubulin polymerization to disrupt microtubules and arrest myeloma
cells at the G2/M checkpoint [21]. Of note, the protease-resistant properties of the linker used in
belamaf requires lysosomal degradation of the attached antibody for the release of MMAF in the cell.
The use of non-cleavable linkers helps to prevent the side effects of premature release of the toxic
payload before it is internalized by the MM cells [25].
8. Pharmacokinetics
The pharmacokinetic profile of belantamab mafodotin was evaluated as a secondary endpoint of a
dose-escalation and expansion of the phase I trial. Methods, including population pharmacokinetics and
conventional allometry demonstrated linear, dose-proportionality. Current dosage and administration
recommendations are based on Phase II DREAMM-2 study findings, which supported recent accelerated
FDA approval of belamaf.
Clinically significant demographic differences in pharmacokinetics of belamaf were not observed
in the study patients (34–89 years, male vs. female, white vs. black, 42–130 kg in weight). Additionally,
inconsistencies in pharmacokinetics were not observed in physiologic disturbances, including
mild hepatic impairment (defined as total bilirubin ≤ULN and AST >ULN or total bilirubin 1 to
≤1.5 x ULN and any AST) and mild renal impairment (defined as eGFR 30–89 mL/min/1.73 m2). Further
investigation is needed to determine the implications of severe renal impairment (ESRD with eGFR
<15 mL/min/1.73 m2) or moderate to severe hepatic impairment on the pharmacokinetics of belamaf,
as these data are not available at this time [82].
8.1. Absorption and Distribution
Belantamab mafodotin is administered as an intravenous infusion, and FDA guidelines advise
a dosage of 2.5 mg/kg over the course of 30 min every three weeks [82]. The 2.5 mg/kg dose was
further investigated, based on its preferable safety profile and comparable anti-myeloma activity to the
3.4 mg/kg dose [80]. An exposure–response relationship was not observed at 2.5 or 3.4 kg/mg after
controlling for the effect of existing disease-related variables [89]. There was no reported evidence of
large QTc prolongation (>10 ms) at the recommended dosage of 2.5 mg/kg once every three weeks.
Levels of belantamab, parent antibody, and total antibody were observed at maximum
concentrations at the completion of the 30-min infusions, in comparison to the activated cytotoxic
drug (cys-mcMMAF) levels, which were shown to peak about 24 h after doses were administered [89].
Approximately 70% of accumulation was observed with the above dosing regimen. The time to reach
a steady state was approximately 70 days. The mean steady-state volume of distribution was 11 L
(15%) [82]. The steady-state volume of distribution (Vss) was documented at 4.2 L, which aligns with
the characteristic Vss for a monoclonal antibody. This Vss value suggests that the distribution of
belamaf is mainly restricted to the systemic circulation and interstitial space [89].
8.2. Metabolism
The mechanism of metabolism is anticipated to occur via the catabolic processing of the monoclonal
antibody portion into single amino acids and small peptides. The cyclic isomer form of the active
cytotoxic payload, cys-mcMMAF, was metabolized by hydrolysis and dehydration in vitro [82].
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8.3. Elimination
The terminal phase half-life was 12 days following the first dose and 14 days when a steady
state was reached [82]. Slow total plasma clearance was noted at 0.37 L/d, with a gradual decrease in
clearance over time. Compared with plasma clearance after the first dose (0.9 L/day (42%)), the total
plasma clearance was roughly 22% lower at steady state [82].
9. Clinical Studies: Safety and Efficacy
9.1. Phase I Studies: DREAMM-1 Trial
DREAMM-1, a phase I clinical trial, analyzed the safety and clinical efficacy of GSK2857916
(belantamab mafodotin) and consisted of two parts. Part I, the dose-escalation phase, explored the
drug’s safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) in
multiple myeloma patients with progressive and refractory disease (Table 2). A total of 38 patients
were treated in part 1 (0.03–4.60 mg/kg) via one-hour intravenous infusions once every three weeks
for a maximum of 16 total treatments. The National Cancer Institute Common Criteria for Adverse
Events version 4.0 was utilized to define adverse events (AEs). In part I, 53% (20/38) of patients
developed corneal AEs, 90% of which were categorized as grade I–II. Grade IV–V corneal AEs did not
occur [89]. Of note, all patients were pretreated with steroid eye drops prior to belamaf infusion due
to evidence of monomethyl auristatin F (MMAF)-induced corneal toxicity occurring with previously
studied antibody-conjugate drugs [90]. The most common grade III AE was anemia, developing in
16% of patients. Thrombocytopenia accounted for 4 of the 7 grade IV AEs. Overall, belamaf was
well tolerated with no MTD or dose-limiting toxicities developing in part I of the study. An RP2D of
3.40 mg/kg was determined based on a 100% response rate occurring in three patients at this dosage
with additional consideration to lower tolerability observed at higher dosages [89].
The primary endpoint of part II, the expansion phase, focused on the tolerability, safety, PK,
and clinical activity of the RP2D (3.4 mg/kg) (Table 2). The most frequently observed AEs in these
patients was blurry vision (45%) at a grade 1–2 severity. The data are in concordance with a previous
study concerning ocular AE in antibody-combination therapy in which blurred vision was the most
commonly observed sequela [90]. Thrombocytopenia was, once again, the most common grade IV AE,
occurring in approximately 9% of patients. As in part I, no grade V AEs were observed. Additionally,
no deaths were attributed to the drug throughout the phase I trial. Concerning the efficacy of the RP2D,
a 60% overall response rate (ORR) was achieved with a 95% CI: (42.1–76.1). A stringent complete
response (sCR) occurred in 3% of patients (n = 1), a complete response (CR) was observed in 6% of
patients (n = 2), and a very good partial response (VGPR) occurred in >40% of patients (n = 16). Of
those previously treated with greater than five lines of therapy (29 patients), ORR was 46.2% (95% CI:
19.2–74.9). Approximately 60% (n = 38) of patients, refractory to proteasome inhibitor therapy, achieved
an ORR of 58.8% (95% CI: 40.7–75.4). At this stage in the study, the median progression-free survival
(PFS) was approximated at 7.9 months (95% CI: 3.1–not estimable) [89].
An update in the phase I trial was published after an additional 14 months of follow-up, revealing
an identical ORR, but with one additional response occurring in both the sCR (two patients) and CR
(three patients) categories (Table 2). Median PFS was approximated at 14.3 months (95% CI: 3.1–not
estimable), with the average first response occurring within two months of treatment. Concerning those
without a prior history of daratumumab therapy (21 patients), an ORR was achieved in 71.4% (95% CI:
47.8–88.7). Of patients refractory to previous daratumumab therapy (13 patients), 38.5% attained an
ORR (95% CI: 13.9–68.4). This data, although from a small cohort, may suggest much lower drug
activity in daratumumab refractory patient populations. Safety profiles reflected previous trends with
corneal events as the most commonly experienced sequela of treatment [7]. In summary, this phase I
clinical trial achieved its primary endpoint, as the RP2D proved efficacious in the treatment of a small
cohort of refractory multiple myeloma patients with minimization of serious AE.
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Table 2. Clinical Efficacy and Safety.
Author
(Year) Groups Studied and Intervention Results and Findings Conclusions
Trudel S. et al. (2018)
[7,89]
DREAMM-1 trial:
Patients with progressive and
refractory multiple myeloma were
treated with belamaf once every 3
weeks for a maximum of 16 treatments.
Thirty-eight patients were included in
the dose-escalation phase, with the
dose-expansion phase consisting of
thirty-five patients.
Dose escalations phase:
Three patients receiving 3.4 mg/kg of drug therapy achieved an
100% response rate. Corneal events were the most commonly
experienced adverse effect (AE) occurring in 53% of patients.
Anemia was the most common grade III AE, and
thrombocytopenia was the most frequently observed grade IV
AE. A dosage of 3.4 mg/kg was designated as the recommended
phase II dose (RP2D) based on data suggesting an acceptable
efficacy and safety profile.
Dose expansion phase:
A 60% overall response rate (ORR) was achieved in those
receiving 3.4 mg/kg of therapy with >40% of patients achieving a
very good response rate (VGPR). Stringent complete response
(sCR) was attained in one patient.
Data from this phase I study suggest
belamaf is efficacious and
well-tolerated in those with multiple
myeloma refractory to multiple lines
of therapy.
Lonial S. et al.
(2020) [65,66]
DREAMM-2 trial:
Analyzed the clinical efficacy and
safety of belamaf in two treatment
cohorts at dosages 2.5 mg/kg (97
patients) and 3.4 mg/kg (99 patients).
Both groups had received a median of
6 prior lines of therapy.
2.5 mg/kg cohort:
31% of patients achieved an ORR with a VGPR observed in 18.5%
of individuals. An estimated progression free survival (PFS) of
2.9 months was observed.
3.4 mg/kg cohort:
An ORR was attained in 34% of patients in this treatment group.
PFS was approximately 4.9 months.
Median time to response was within 2 months in both treatment
cohorts. Corneal events, anemia, and thrombocytopenia were the
most commonly occurring AE with evidence of serious AEs
observed in over 40% of patients at both dosages. Nearly half of
patients with grade II ocular AEs had return to baseline corneal
architecture following cessation of belamaf therapy.
Belamaf at dosages 2.5 mg/kg and 3.4
mg/kg proved to be clinically
efficacious in patients that were
refractory to a median of ≥6 lines of
therapy. The 2.5 mg/kg cohort
experienced similar results with
reduced AE in comparison to those
receiving higher dosage. Phase III
studies are needed to evaluate
efficacy in comparison to standard
therapy modalities.
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9.2. Phase II Studies: DREAMM-2 Trial
DREAMM-2, a randomized two-arm phase II study, focused on the safety and efficacy of belamaf
in patients with refractory multiple myeloma who were allocated into two dosage cohorts: 2.5 mg/kg
(97 patients) or 3.4 mg/kg (99 patients) (Table 2). These dosages were chosen based on the positive
clinical responses achieved in the phase I study. The primary endpoint entailed the ORR achieved in
both cohorts of treatment. Of those who received 2.5 mg/kg of treatment, an ORR of 31% (95% CI:
20.8–42.6) was observed, with 18 patients (18.5%) achieving a VGPR (median time to follow-up
6.3 months). Of those who received 3.4 mg/kg of therapy, a 34% ORR (95% CI: 23.9–46) was achieved
(median time to follow-up 6.9 months). The median time to response was within two months for both
cohorts with an accompanying progression-free survival of 2.9 months and 4.9 months in the lowest
and highest dose groups, respectively.
As with the DREAMM-1 trial, corneal events, thrombocytopenia, and anemia were the most
prevalent AEs reported. Specifically, corneal events occurred in 70.5% of the 2.5 mg/kg group and
in 76.8% of the 3.4 mg/kg group, with 27% and 33% of patients experiencing grade III–IV AEs,
respectively. Interestingly, topical steroid prophylaxis was not proven beneficial in preventing ocular
AEs [66]. Twenty percent of patients in the low dose arm experienced grade III–IV thrombocytopenia
in comparison to 33% of patients who received the higher dose therapy. Over 40% of patients in both
cohorts had evidence of serious AEs, with one death occurring in each cohort that was not unattributable
to the drug (sepsis in 2.5 mg/kg group; hemophagocytic lymphohistiocytosis in 3.4 mg/kg group).
Of note, patients included in DREAMM-2 had more progressive disease and were more refractory to
previous medical therapy (median of 6 prior lines of treatment in 2.5 mg/kg cohort; 7 lines in 3.4 mg/kg
cohort) in comparison to those included in the DREAAM-1 trial [65,89].
Due to the known corneal toxicity potential of MMAF, corneal AEs were further analyzed,
utilizing data from the 2.5 mg/kg cohort in the DREAMM-2 trial (Table 2). As in the DREAMM-1 trial,
patients received prophylactic steroid eye solution before belamaf therapy. Prior studies concerning
antibody-drug conjugate associated epithelial changes have shown inconsistent evidence of steroid
prophylaxis efficacy; however, studies focused specifically on the prevention of microcyst-like epithelial
changes (MEC) are scarce. MEC were defined as the disruption of epithelium architecture noted
by ophthalmologist-conducted slit-lamp examination. These lesions manifested in patients as small
polymorphous opacities limited to the corneal epithelium. Such changes are theorized to result from
drug-induced apoptosis, following macropinocytosis of belamaf’s MMAF moiety by corneocytes.
Patients also received a best-corrected visual acuity (BCVA) assessment prior to participation in the trial.
The MEC and BCVA were subsequently graded utilizing the keratopathy and visual acuity (KVA) scale.
According to data analysis, grade I–II (mild-moderate) MEC occurred in 25% of patients, grade III
events were observed in 45%, with only 1% of patients experienced grade IV MEC (severe) [66].
The most common ocular symptoms included blurred vision (21% of patients) and dry eyes
(15% of patients). Of those who developed any ocular side-effects, 25% had evidence of MEC following
the first administration of belamaf. Despite MEC occurring in the majority of patients, nearly 50% of
patients with grade II or higher MEC recovered to baseline corneal architecture. Although these results
are promising, the use of topical steroids potentially confounds the accuracy of this data. Of those
who reported symptoms of blurry vision and dry eyes, 63% and 79% achieved recovery, respectively.
As previously mentioned, steroid prophylaxis did not appear to have a statistically significant beneficial
impact on the prevention of corneal events in the DREAMM-2 trial. Change in BCVA occurred in 54%
of patients, with the majority of events labeled as grade III. Of those with grade II or greater change,
approximately 60% returned to baseline BCVA as in the last follow-up [66]. Whilst the DREAMM-2
trial provides insight into the ocular effects of belamaf, additional research regarding incidence and
resolution of MEC is necessary to determine the best ophthalmologic management of these patients
with concurrent optimization of therapy. Current clinical trials are planned to further characterize
corneal epitheliopathy in patients treated with belamaf (NCT04549363).
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9.3. Case Series
A case series including five patients treated with 3.4 mg/kg belamaf once every 3 weeks aimed to
characterize belamaf-related corneal events. Topical steroid prophylaxis was utilized prior to belamaf
administration, and symptoms of blurry vision and dry eyes were managed with preservative-free
(PF) eye lubricant drops and increased frequency of steroid use. All five patients experienced corneal
events, with three of the five developing grade III AEs over a median follow-up period of 32.6 months.
Due to these ocular sequelae, each patient required dose interruptions, and all patients received two
dose reductions throughout the duration of treatment. No patients experienced grade IV or V corneal
AEs. Of note, upon the cessation of belamaf therapy, all patients attained resolution of grade III or
above AEs within one year of the last dose. Although the optimal management of belamaf-related
ocular events is yet to be determined, the authors of this study recommend limiting the extended
use of topical steroids while utilizing PF lubricant drops and dose modifications. Regarding belamaf
efficacy in this small study, two patients attained an sCR, with a CR occurring in one patient, and a
VGPR achieved in two patients [91].
9.4. Indirect Comparison Study
One study analyzed the clinical efficacy of belamaf monotherapy versus selinexor (nuclear export
protein 1 inhibitor) plus dexamethasone (sel+dex) via an indirect comparison in multiple myeloma
patients refractory to anti-CD38 therapy. Data from the DREAM-2 trials were utilized to generate
matching-adjusted indirect comparisons. Belamaf treatment was found to be superior to the sel+dex
duration of response (Hazard Ratio: 0.34) and overall survival (Hazard Ratio: 0.60). No statistical
significance was observed in the overall response rate, progression-free survival, or time to response
between the two treatment regiments [92]. Direct comparisons with increased statistical power will be
required to provide convincing evidence of belamaf superiority with regard to sel+dex in the treatment
of refractory multiple myeloma.
9.5. Future Studies
Following the results of the DREAMM-1 and two trials, multiple studies concerning belantamab
mafodotin are currently in the pipelines, with several of these studies actively recruiting patients
(Table 3). The focuses of these upcoming trials include the efficacy and safety of belamaf in
comparison to pomalidomide plus low-dose dexamethasone (DREAMM-3), belamaf in combination
with pembrolizumab (DREAMM-4), and belamaf in combination with lenalidomide or bortezomib
plus dexamethasone (DREAMM-6) [93–95]. The DREAMM-5 trial aims to analyze the efficacy of
belamaf plus various anti-cancer drugs, including GSK335609 (inducible T-cell costimulatory agonist),
nirogacestat (gamma secretase inhibitor), and GSK317498 (selective OX40 agonist) [96–98]. At the
time of this review, no direct head-to-head comparisons of belamaf vs. other agents have been
performed; however, the DREAMM-7 trial plans to study the clinical efficacy of belamaf in combination
with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus
dexamethasone. DREAMM-8 plans to compare the safety and efficacy of belamaf in combination
with pomalidomide and dexamethasone versus bortezomib in combination with pomalidomide and
dexamethasone. The DREAMM-9 and 10 trials plan to compare belamaf versus the standard of care
for multiple myeloma [98]. DREAMM-12 and 13 trials will assess safety and tolerability of belamaf in
patients with normal or impaired renal or hepatic function, respectively, So far, belamaf has provided
promising evidence of clinical efficacy with manageable adverse effects for patients with progressive
and refractory multiple myeloma; however, future DREAMM trials are required to determine an
optimal treatment approach and effective risk-management strategies.
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Table 3. Ongoing Clinical Trials of Belantamab Mafodotin in Multiple Myeloma.
Phase Identifier EN, n Drug(s) Indication Prior Anti-myelomaTreatments, N of lines Status
Phase III NCT04162210,DREAMM-3 380
Arm A: Belantamab mafodotin Arm
B: Pomalidomide + Dexamethasone RRMM ≥2 Recruiting












Phase I/II NCT03544281,DREAMM-6 152
Arm A: Belantamab mafodotin,
Dexamethasone, Lenalidomide
Arm B: Belantamab mafodotin,
Dexamethasone, Bortezomib
RRMM ≥1 Recruiting
Phase III NCT04246047,DREAMM-7 478
Arm A: Belantamab mafodotin,
Bortezomib, Dexamethasone
Arm B: Daratumumab, Bortezomib,
Dexamethasone
RRMM ≥1 Recruiting
Phase III NCT04484623,DREAMM-8 450
Arm A: Belantamab mafodotin,
pomalidomide, dexamethasone
Arm B: Bortezomib, pomalidomide,
dexamethasone
RRMM ≥1 Recruiting







Phase I NCT04398745,DREAMM-12 36 Belantamab mafodotin RRMM ≥2 Recruiting
Phase I NCT04398680,DREAMM-13 24 Belantamab mafodotin RRMM ≥2 Not Yet Recruiting
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Table 3. Cont.
Phase Identifier EN, n Drug(s) Indication Prior Anti-myelomaTreatments, N of lines Status





- Not Yet Recruiting
Phase I/II NCT03715478,ALGONQUIN 62
Belantamab mafodotin
Pomalidomide Dexamethasone RRMM ≥2 Recruiting
Phase I NCT04177823 5 Belantamab mafodotin RRMM ≥2 Active, NotRecruiting
Phase II NCT04680468 47 Belantamab mafodotin prior tomelphalan + ASCT RRMM ≤2 Not Yet Recruiting





RRMM ≥3 Active, NotRecruiting
Phase I NCT03828292 14
Part 1: Belantamab mafodotin
monotherapy
Arm A: Belantamab mafodotin +
Bortezomib/Dexamethasone
Arm B: Belantamab mafodotin +
Pomalidomide/Dexamethasone
RRMM ≥2 Recruiting
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10. Conclusions
Multiple myeloma is a hematologic malignancy characterized by the excessive clonal proliferation
of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the
complex molecular pathophysiology and incurable status of the disease at this time. Given that MM is
the second most common blood cancer with a characteristic and unavoidable relapse/refractory state
during the course of the disease, the development of new therapeutic modalities remains crucial.
Belantamab mafodotin (belamaf) was designated as a breakthrough therapy for heavily pretreated
patients with relapsed/refractory multiple myeloma in November 2017 and continues to show promise
as a unique modality for future treatment regimens with recent accelerated FDA approval. Belamaf
offers a unique combination of therapeutic mechanisms as an antibody drug conjugate with exclusive
antitumor activity in MM tumor cells via BCMA binding. The IgG1 mAb component not only confers
specificity but also induces an immune response, resulting in ADCC and ADCP along with the
induction of apoptosis via the toxic payload (MMAF).
While several investigational therapeutics with anti-BCMA activity are being investigated at this
time, belantamab mafodotin offers the benefits of an off-the-shelf therapy that is administered once
every three weeks. The most prominent adverse events include corneal toxicity, thrombocytopenia,
and anemia associated with the MMAF payload. Specific prophylaxis or treatment guidelines for
belamaf-related keratopathy are not known, as the underlying mechanism of this toxicity remains
unclear. Corticosteroid eye drops were not found to reduce the frequency of keratopathy in clinical
studies. Current management strategies include mainly dose modifications (delays and reductions) to
allow for the regeneration of corneal epithelial cells and PF lubricant drops. Other strategies include
cooling eye masks or vasoconstrictors administered at the start of the infusion. However, the true
benefit of these mitigation strategies remains unclear.
Based on the DREAMM-2 evidence of 31% of patients achieving an ORR and a very good response
rate observed in 18.5% of individuals, belamaf is a valid treatment option for MM patients who have
exhausted multiple standard therapies. Future phase III studies are necessary to evaluate efficacy
in comparison to other standard treatment modalities. Additional planned DREAMM trials will be
aimed at determining the utility of belantamab mafodotin in combination with other current MM
drugs, including protease inhibitors, monoclonal antibodies, and corticosteroids. Further research is
needed to define ocular toxicity mitigation strategies, the potential benefits of belamaf use for early
MM, potential synergistic therapeutic combinations, and the durability of drug-induced immunogenic
responses to myeloma cells.
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